Athersys Inc.

Athersys Inc. is a clinical-stage biotechnology company developing MultiStem, a patented, adult-derived "off-the-shelf" stem cell product platform for the cardiovascular, neurological, inflammatory and immune disease areas. The company currently has five clinical stage programs involving MultiStem, including those for treating inflammatory bowel disease (partnered with Pfizer Inc.), ischemic stroke, damage caused by myocardial infarction and for the prevention of graft-versus-host disease. Athersys has additional pharmaceutical programs in the metabolic and neurological areas, and a broad international network of collaborations with leading clinical and research institutions.

Expert Comments:

Jon Crowley, Seeking Alpha (5/10/16)
“Despite Athersys’ recent run up, positive data from its stroke acute respiratory distress syndrome (ARDS) trial could drive the price up much farther. . .Similarly to stroke ARDS is notoriously difficult to treat with limited treatment options. . .Athersys believes MultiStem can be beneficial to patients suffering from ARDS. . .the United Kingdom and the NIH believe MultiStem can be beneficial for ARDS as well and have committed funding to help study MultiStem for ARDS. . .this is a huge patient population that is a largely unmet medical need."

Jason Kolbert, Maxim Group (5/6/16)
"Athersys Inc. and Healios are approaching the start of the Japan trial; we are excited as the start approaches. We look forward to the stroke trial (a large and robust study) design (to achieve statistical significance) with 150-200 patients. . .there is unusually strong alignment and interest in both parties to expand MultiStem to other indications for Japan."

Wall Street Titan, Seeking Alpha (4/27/16)
"Athersys Inc. officially put the Chugai saga behind it with a new, expanded agreement with Healios. . .Healios is responsible for all development costs [for MultiStem] in Japan as Athersys maintains a lucrative portion of the upside. . .some unexpected 'excellent' news came on Feb. 17, 2016, with the release of follow-up Phase 2 365-day stroke data; the MultiStem-treated group of patients continued to improve above and beyond the placebo group for a measurement called 'Excellent Outcome'. . .with its new partner, Healios, Athersys has turned the page on 2015 and set itself up for an exciting future."

Jefferson Research (4/8/16)
"Athersys Inc. is showing strong cash flow quality, operating efficiency, balance sheet quality and earnings quality, and valuation suggests a lower amount of price risk. . .the company's ability to earn a profit is in part the result of how rapidly it converts its collection of assets into revenues and the resulting percentage available in earnings and cash flow after expenses have been paid. . .the balance sheet shows the ability of Athersys to pay its bills and fund future growth."

Maxim Jacobs, Edison Investment Research (3/24/16)
"Athersys Inc. recently signed a partnership agreement with Healios in Japan for stroke and other indications. A Phase 2 trial with MultiStem in acute myocardial infarction is underway with data expected in H2/16, and a Phase 2a study for acute respiratory distress syndrome will be initiated soon."

Jason Kolbert, Maxim Group (3/11/16)
"Given the building data that suggests Athersys Inc.'s MultiStem works (and that stem cell therapy works in multiple modalities), we are lowering our risk rating (to 20%, from 30%). This drives a price target increase to $10, from $5. While the challenge in reaching our price target remains the catalyst (a 2017 event), we believe that smart investors who take the time to evaluate the data will see that a positive outcome for MultiStem in stroke is probable."

More Expert Comments

Experts Following This Company

Katherine Genis, Analyst – Edison Investment Research
Maxim Jacobs – Edison Investment Research
Jason Kolbert, Senior Analyst – Maxim Group
Jason McCarthy, Analyst – Maxim Group
Henry McCusker, Founder and Director of Research – Scimitar Equity
Henry McCusker RegMed Investors
Ram Selvaraju, Managing Director; Head of Healthcare Equity Research – Rodman & Renshaw

The information provided above is from analysts, newsletters, the company and other contributors.

Athersys Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.